Abstract
In addition to being accepted therapy in hypertension and heart failure, ACE inhibitors may well offer a new dimension in anti-ischaemic therapy. Currently, anti-ischaemic properties have been demonstrated by ACE inhibitors in selected patient groups, including patients with left ventricular dysfunction with or without a direct temporal relationship with myocardial infarction. Anti-ischaemic effects of ACE inhibitors become apparent late after initiation of treatment and suggest a structural rather than a functional effect. Underlying mechanisms may include a reduction in ventricular dilatation and (abnormal) cardiac hypertrophy, leading to less myocardial oxygen demand and, possibly, improved subendocardial blood supply, and vasculoprotective effects, i.e. anti-atherosclerotic and antiremodelling properties, a beneficial effect on the fibrinolytic system and an improvement in abnormal endothelial vasodilator function. The latter aspect is most probably the pivotal mode of action where the anti-ischaemic profile of ACE inhibition is concerned. An improvement in endothelial dysfunction has been shown in patients with mild to moderate coronary artery disease [Trial on Reversing ENdothelial Dysfunction (TREND)]. It is of importanc...Continue Reading
Citations
Jul 14, 2000·Clinical Cardiology·W J Remme
Jul 14, 2000·Clinical Cardiology·B Pitt
Dec 21, 2000·Current Atherosclerosis Reports·N Sharma, T C Andrews
Sep 28, 2010·Cardiovascular Toxicology·Afolabi C AkinmoladunEbenezer O Farombi
Nov 5, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·K K Veeravalli, A Akula
Jan 13, 2001·The Annals of Thoracic Surgery·J FengE R Rosenkranz
Jun 13, 2001·Journal of the American College of Cardiology·M E KhalilI A Alhaddad
Oct 7, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·K K VeeravalliM K Kota
Jul 9, 2002·Clinical and Experimental Pharmacology & Physiology·Henry H HolzgrefeJames R Powell
Aug 7, 2002·The Journal of Clinical Investigation·Joost P SchanstraJean-Loup Bascands
Jun 4, 1999·Journal of Clinical Pharmacology·M M McConnaugheyA J Ingenito
Sep 1, 2000·Lancet·J L RouleauA J Block
Dec 10, 1999·The Annals of Thoracic Surgery·J Feng, E R Rosenkranz
Mar 21, 2000·Journal of Molecular and Cellular Cardiology·M Maczewski, A Beresewicz
Feb 15, 2000·Journal of Cardiovascular Pharmacology·X ZhangT H Hintze
Sep 9, 2004·Japanese Heart Journal·Hsin-Bang LeuPhilip Yu-An Ding
May 21, 2005·The American Journal of Cardiology·Bernard R ChaitmanJohn H Lawrence
Apr 20, 2005·International Journal of Cardiology·Dimitris TousoulisChristodoulos Stefanadis
May 2, 2001·The American Journal of Medicine·R TabibiazarS G Rockson
Feb 24, 2012·International Journal of Cardiology·Alison L MüllerNaranjan S Dhalla
Jan 27, 2015·Cell Biochemistry and Biophysics·Ou YangJian Kong
Jan 13, 2015·Vascular Pharmacology·Domenico Regoli, Fernand Gobeil
Jul 31, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·M J ZurbanoG Escolar
Feb 6, 2002·Circulation·Maria E Marin-CastañoJean-Loup Bascands
Sep 22, 2001·Hypertension·S SanadaM Hori
Apr 13, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yasuyuki TanakaSeibu Mochizuki
Sep 24, 2021·Acta Physiologica·Philipp HillmeisterIvo Buschmann